Cancer drug developers SuperGen Inc. and Astex Therapeutics Ltd. will merge in a deal that will pay Astex shareholders $25 million upfront and SuperGen stock as well as deferred compensation of $30 million in stock or cash over 30 months, the companies said late Wednesday.
Dublin-based SuperGen (NASDAQ: SUPG) and Astex, based in Cambridge, United Kingdom, expect the deal to close in July, subject to regulatory and shareholder approvals.
No comments:
Post a Comment